Bio/Pharma Business

Results from our annual survey. This article contains online bonus material and is part of a special issue on Bioprocessing and Sterile Manufacturing.

The Women in the World Summit, which was held in New York in March, focused on issues and solutions for improving the economic, political, and social rights of women globally, including a focus on global health initiatives.

Eli Lilly and GlaxoSmithKline are among several pharmaceutical companies using technology transfer as way to improve health outcomes in the developing world.

This article, which focuses on manufacturing and drug access, is Part II of a three-part series on biopharmaceutical issues in public health, government, and developing world markets.

A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Europe's approach to pharmacovigilance has room for improvement that European agencies are working on.

Pharmaceutical Technology's annual survey on equipment and machinery reveals the spending levels and type of spending made in 2010 and planned for 2011.

A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Bristol-Myers Squibb opens a new pediatric HIV/AIDS clinic in Tanzania.

This article is Part I of a three-part series on biopharmaceutical issues in public health, government, and developing-world markets. Part 1 focuses on drug-development. Part II, which examines manufacturing, appeared in the April 2011 of Sourcing and Management. Part III, which analyzes distribution and administration,appeared in the May 2011 issue.

The Novartis Foundation for Sustainable Development held a symposium in December 2010 to continue dialogue on how the private and public sector can work together in achieving the UN Millennium Development Goals.

USP helps to improve drug quality in 32 countries.

One year following the earthquake in Haiti, the pharmaceutical industry and private sector participate in efforts for long-term relief.

A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Direct-to-consumer (DTC) advertising is firmly entrenched in the US, but has historically been considered as an inappropriate means of communication in Europe for prescription-only medicines.

An assessment of the progress and needed activity to achieve global sustainability goals shows Brazil and India leading G20 economies.

A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Representatives from the United Nations, governments, businesses, and nonprofit groups met in Cancún, Mexico, to move forward international efforts for meeting climate-change goals.

The Global Health Progress collaboration works to improve healthcare delivery in the developing world.

Tiered pricing is used throughout industry to help increase affordability and access to drugs in the developing world.

A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

The Global Reporting Initiative begins an effort to increase the level and strength of sustainability reporting among US-based corporations.

The prevention and treatment of noncommunicable diseases is becoming an increasingly important consideration in global health initiatives.

An annual analysis rates the performance of pharmaceutical and biotechnology companies in corporate sustainability.

World leaders gathered at the United Nations last month to review the progress and map out a strategy for achieving the Millennium Development Goals.

A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

A look at MVI's malaria work in developing countries.

Despite the poor economic climate, large-scale mergers and acquisitions in the pharmaceutical industry struck back with a vengeance in 2009.

An upcoming summit will assess the progress and gaps in realizing the UN Millennium Development Goals, including outcomes from global health initiatives.